Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study

被引:2
作者
Chen, Jie [1 ]
Chang, Jing [1 ]
Shi, Qiuyue [1 ]
Li, Xin [1 ]
Wang, Ling [1 ]
Zhao, Hong [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing 400010, Peoples R China
关键词
Sodium-glucose cotransporter 2 inhibitors; Acute coronary syndrome; Type 2 diabetes mellitus; MORTALITY; EMPAGLIFLOZIN; METAANALYSIS; OUTCOMES;
D O I
10.1186/s12872-023-03542-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAcute coronary syndrome (ACS) remains the leading cause of death and disability worldwide, especially when combined with type 2 diabetes mellitus (T2DM). Many multicenter randomized controlled trials have established the cardiovascular benefits of Sodium-Glucose cotransporter 2 inhibitors (SGLT-2i) in patients with T2DM at high cardiovascular risk. However, these studies did not include patients in the early stages of acute coronary events. This study investigated the cardiovascular protective effects of SGLT-2i in patients with ACS and T2DM.MethodsA total of 232 hospitalized patients with ACS and T2DM were enrolled and divided into two groups based on their hypoglycemic drug treatment: the SGLT-2i and the non-SGLT-2i groups. Kaplan-Meier analysis and Cox regression were used to compare adverse cardiovascular outcomes in both groups.ResultsThere were no significant differences in the hospital clinical outcomes between the SGLT-2i and non-SGLT-2i groups. The adverse cardiovascular outcomes did not significantly differ between both groups (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.35-1.25, P = 0.195). Moreover, the rehospitalization rates for ACS or heart failure (HF) were not significantly different between both groups (adjusted HR 0.56, 95%CI 0.28-1.10, P = 0.093). When analyzed separately, there was no significant difference in rehospitalizations for ACS (HR 0.87, 95% CI 0.40-1.87, P = 0.713). However, the SGLT-2i group showed lower rates of rehospitalizations for HF (adjusted HR 0.20, 95% CI 0.04-0.96, P = 0.045). Additionally, there was no significant difference in cardiovascular mortality between both groups (HR 1.75, 95% CI 0.28-10.97, P = 0.543). Notably, the SGLT-2i group exhibited a higher angina symptom control rate than the non-SGLT-2i group (adjusted odd ration (OR) 0.45, 95%CI 0.21-0.93, P = 0.031).ConclusionIn recently diagnosed patients with ACS, who have T2DM, early initiation of SGLT-2i was associated with a lower risk of rehospitalization for HF and a higher rate of angina symptom control.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?
    Snaith, Jennifer R.
    Greenfield, Jerry R.
    MEDICAL JOURNAL OF AUSTRALIA, 2022, 217 (03) : 126 - 128
  • [22] Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
    Carlson, Curt J.
    Santamarina, Marile L.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) : 1401 - 1412
  • [23] Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
    Kwon, Chang Hee
    Kim, Ye-Jee
    Kim, Min-Ju
    Cha, Myung-Jin
    Cho, Min Soo
    Nam, Gi-Byoung
    Choi, Kee-Joon
    Kim, Jun
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 178 : 35 - 42
  • [24] Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes
    Siamashvili, Maka
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2181 - 2198
  • [25] Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary C.
    Zakoul, Heidi
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA INTERNAL MEDICINE, 2024, 184 (03) : 265 - 274
  • [26] A systematic review of sodium-glucose cotransporter 2 inhibitors and renal profiles among Japanese patients with type 2 diabetes mellitus
    Mukai, Junichi
    Okamura, Nakaba
    Saito, Yuki
    Kubota, Rie
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2023, 9 (01)
  • [27] Effect of sodium-glucose cotransporter 2 inhibitors on serum low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus
    Imada, Tasuku
    Katakami, Naoto
    Watanabe, Hirotaka
    Nishina, Shuhei
    Sasaki, Shugo
    Takahara, Mitsuyoshi
    Shimomura, Iichiro
    Yamamoto, Tsunehiko
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (07) : 843 - 850
  • [28] Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Arnott, Clare
    Li, Qiang
    Kang, Amy
    Neuen, Brendon L.
    Bompoint, Severine
    Lam, Carolyn S. P.
    Rodgers, Anthony
    Mahaffey, Kenneth W.
    Cannon, Christopher P.
    Perkovic, Vlado
    Jardine, Meg J.
    Neal, Bruce
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (03):
  • [29] Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis
    Tao Liu
    Zeyuan Fan
    Bing Xiao
    Chang He
    Shicong Wang
    Cardiovascular Diabetology, 23
  • [30] Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes
    Dawwas, Ghadeer K.
    Smith, Steven M.
    Park, Haesuk
    DIABETES OBESITY & METABOLISM, 2019, 21 (01) : 28 - 36